CAJ | 학술논문

目的：探讨联用阿立哌唑对改善抗精神病药物所致高催乳激素血症的疗效及安全性。方法对70例服用其它单一抗精神病药物治疗且剂量固定4周以上精神分裂症患者，根据随机数字表法分为治疗组35例，对照组35例。治疗组在服用原药的基础上，每天联用阿立哌唑2．5 mg，对照组维持以前的药物治疗。两组均在治疗前及治疗第4周末分别测定患者血清催乳激素水平，并进行比较。同时用阳性和阴性症状量表（PANSS）评定临床症状程度，不良副反应量表（TESS）评定不良反应情况。结果治疗组患者血清催乳激素水平明显下降[（78．64±30．15）μg／L与（35．01±13．99）μg／L，t＝9．585，P＜0．05]，对照组血清催乳激素水平无明显变化[（80．34±46．08）μg／L与（79．94±43．84）μg／L，t＝0．084，P＞0．05]。两组PANSS、TESS评分差异均无统计学意义（均P＞0．05）。结论联用阿立哌唑对抗精神病药物所致高催乳激素血症有一定的治疗作用，并且相对安全。
목적：탐토련용아립고서대개선항정신병약물소치고최유격소혈증적료효급안전성。방법대70례복용기타단일항정신병약물치료차제량고정4주이상정신분렬증환자，근거수궤수자표법분위치료조35례，대조조35례。치료조재복용원약적기출상，매천련용아립고서2．5 mg，대조조유지이전적약물치료。량조균재치료전급치료제4주말분별측정환자혈청최유격소수평，병진행비교。동시용양성화음성증상량표（PANSS）평정림상증상정도，불량부반응량표（TESS）평정불량반응정황。결과치료조환자혈청최유격소수평명현하강[（78．64±30．15）μg／L여（35．01±13．99）μg／L，t＝9．585，P＜0．05]，대조조혈청최유격소수평무명현변화[（80．34±46．08）μg／L여（79．94±43．84）μg／L，t＝0．084，P＞0．05]。량조PANSS、TESS평분차이균무통계학의의（균P＞0．05）。결론련용아립고서대항정신병약물소치고최유격소혈증유일정적치료작용，병차상대안전。
Objective To investigate the efficacy and safety of combined with aripiprazole to improve hyper-prolactinemia caused by antipsychotic drugs.Methods 70 patients with schizophrenia who had been treated with antipsychotic drugs for 4 weeks prior to the study were divided into the two groups by random number table method:the treatment group(35 cases)were given each additionally 2.5 mg of aripiprazole oral,one time every day.The con-trol group (35 cases)continued with no extra management.The treatment group on the basis of the original drug administered daily in combination with aripiprazole 2.5mg,the control group maintained the previous drug treatment. Serum prolactin concentrations were assayed in patients of both groups before treatment and after 4 weeks treatment. At the same time,used the positive and negative symptom scale (PANSS)to assess the state of the clinical symptoms. The side effects were evaluated by Treatment Emergent Symptom Scale(TESS).Results After combined with aripi-prazole,it demonstrated that serum prolactin level in patients of the treatment group were significantly lowered [(78.64 ±30.15)μg/L vs (35.01 ±13.99)μg/L,t=9.585,P<0.05],while those in patients of the control group had no change[(80.34 ±46.08)μg/L vs (79.94 ±43.84)μg/L,t=0.084,P>0.05].There were no significant differences between the two groups of PANSS and TESS scores(all P>0.05 ).Conclusion Combined with aripi-prazole for antipsychotic-induced hyperprolactinemia have a therapeutic effect and relatively safe.